Selective Hsp70/Hsc70 inhibition, antiproliferative, suppression of Her2 and Raf-1, G1 cell cycle arrest, sensitization to 17-AAG and radiation, suppression of Akt and phospho-Akt, macroautophagy induction, suppression of AR-FL and ARV7, apoptosis and paraptosis induction, upregulation of miR-215 and miR-194-5p, degradation of KDMA6 and EP300, degradation of BAG1, upregulation of CHOP, suppression of VEGF release by leukemia cells, synergy effects with drugs (manumycin A, bortezomib, shikonin, 17-DMAG) and PDT [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]. This evidence concerns the gene ERBB2 and leukemia.